91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
, including the increasing adoption of decentralised clinical trials (DCTs) and the growing use of remote monitoring to collect data.
-
Top 10 factors to design and deploy a decentralised clinical trial
Dr. Isaac Rodriguez-Chavez considers the top 10 factors when designing and deploying a decentralised clinical trial.
This article is taken from International Clinical Trials August 2021, pages 8-10. Samedan Ltd.
-
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on .
-
91黑料 CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster ().
-
around the key components of decentralised trials and steps of deployment.
-
91黑料 CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
91黑料 talks about the inclusivity of decentralised trials
Patients as Partners Autumn newsletter (pages 14 & 15) features a Q&A with EB McLindon, Senior VP, Site, Patient and Decentralised Solutions, on the inclusivity of decentralised clinical trials.
-
An article examining , featuring expert commentary from 91黑料's David T. Novotny, General Manager & Global Head, Medical Device & Diagnostic Research.
-
AI in Life Sciences – Covid pushes AI driven clinical trials and drug manufacturing into the limelight
91黑料’s CIO, Tom Leary discusses the challenges to patient recruitment during the COVID pandemic and how big data, combined with advanced AI algorithms processing has the potential to reduce trial costs.
